Roger A. Freedman

Roger A. Freedman

Auto-generated profile, based on publicly available information

Roger A. Freedman

Department of Medicine, University of Utah Health Sciences Center, Salt Lake City (T.S., R.A.F.).

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
RFRoger A. Freedman
Roger A. Freedman
DHDonald L. Hopper
Donald L. Hopper
JMJeng Mah
Jeng Mah
JHJohn Hummel
John Hummel
BWBruce L. Wilkoff
Bruce L. Wilkoff

1 March 2022 in Heart Rhythm
Verified
Journal Article
Closed access
JMJoseph Boone Muhlestein
Joseph Boone Muhlestein
EDElizabeth Dranow
Elizabeth Dranow
JCJason Chaney
Jason Chaney
LNLeenhapong Navaravong
Leenhapong Navaravong
BSBenjamin A. Steinberg
Benjamin A. Steinberg
RFRoger A. Freedman
Roger A. Freedman

23 January 2009 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
RFRoger A. Freedman
Roger A. Freedman
APAlex Petrakian
Alex Petrakian
KBKer Boyce
Ker Boyce
CHCharles Haffajee
Charles Haffajee
JVJesus E. Val‐Mejias
Jesus E. Val‐Mejias
AOAshish L. Oza
Ashish L. Oza

1 January 2001 in Current Opinion in Cardiology
Verified
Journal Article
Closed access
RFRoger A. Freedman
Roger A. Freedman
Recent data have emerged to help guide the use of implantable pacemakers and implantable defibrillators in patients who have hypertrophic cardiomyopathy (HCM). Controlled studies of the use of dual chamber pacemakers to treat outflow tract obstruction in HCM have shown little benefit, and have raised the possibility that earlier favorable reports were demonstrating an element of placebo effect. In particular, there is no recent support for earlier claims of regression of ventricular hypertrophy from chronic dual chamber pacing. Several reports have added to our understanding of the risk factors for sudden death in HCM. A normal blood pressure response to exercise appears to identify a subset of patients at low risk for sudden death. In a recent study of a large number of HCM patients, the risk of sudden death was found to be directly proportional to the extent of left ventricular hypertrophy. There is accumulating evidence that the implantable defibrillator is highly effective in terminating malignant ventricular arrhythmias in HCM patients, and HCM patients thought to be at significant risk for sudden death should be offered defibrillator implantation.

1 December 2025 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
NHNathan Hansen
Nathan Hansen
TSTirah Sheppard
Tirah Sheppard
JMJacob McCoy
Jacob McCoy
RFRoger A. Freedman
Roger A. Freedman
ABAntoni Bayes
Antoni Bayes
BSBenjamin Sanchez
Benjamin Sanchez

23 January 2022 in Heart Rhythm O2
Verified
Journal Article
Open access
RFRoger A. Freedman
Roger A. Freedman
ACAnne B. Curtis
Anne B. Curtis
SDStephanie M. Delgado
Stephanie M. Delgado
LLLi-Yin Lee
Li-Yin Lee
The Cardiac Lead Assessment Study (CLAS) was a large prospective, multicenter, international postmarket surveillance study conducted at 45 sites. The purpose of CLAS was to examine the prevalence and incidence of externalized conductors and electrical dysfunction in subjects with selected St. Jude Medical defibrillator and left ventricular leads. Cinefluoroscopy was used to determine the presence of externalized conductors at enrollment and at 12-, 24-, and 36-month follow-up visits. Lead electrical measurements were collected systematically. The study enrolled 2216 subjects with a total of 2847 study leads. The prevalence of externalized conductors through 36 months for Riata leads was 30.9%, Riata ST leads 12.6%, Durata leads 0.5%, and QuickSite/QuickFlex leads 4.7%. The prevalence of electrical dysfunction through 36 months for Riata was 4.0%, Riata ST 3.3%, Durata 2.4%, and QuickSite/QuickFlex 0.3%. In Riata and Riata ST leads with externalized conductors, there was a low risk of electrical dysfunction. None of the Durata or QuickSite/QuickFlex leads with externalized conductors developed electrical dysfunction. There was no evidence of an electrical short in a high-voltage shocking circuit leading to failed shock. A high prevalence of externalized conductors was found in Riata and Riata ST defibrillator leads, with a higher risk of externalization for 8F Riata leads than for 7F Riata ST leads. The 98% reduction in prevalence of externalized conductors in Durata leads compared to Riata/Riata ST leads confirms that the design improvements culminating in Durata leads significantly improved abrasion resistance and durability.